|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Heart failure due to a variety of causes is accompanied by an upregulation of cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).
|
15135663 |
2004 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
IL-6 mRNA was 2.4-fold higher in unused than in used donors (P:<0.0001) and 4.67-fold higher than in HF (P:<0.0001).
|
11082413 |
2000 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL6 is strongly and independently associated with ASCVD events, HF, and all-cause mortality, particularly among statin users.
|
30312930 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-6 concentration in the plasma of <i>TNFα</i> A-allele carriers at months 1 and 12 after CABG was higher in the HF group compared to the non-HF group (1 month after CABG: 5.3 ± 3.4 vs. 3.1 ± 2.9, p<0.05; 12 months after CABG: 4.2 ± 3,9 vs. 1.4 ± 1.2, p<0.01, respectively).
|
31275366 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
A total of 559 Danish subjects with severe chronic HF enrolled in the previously reported Echocardiography and Heart Outcome Study were genotyped for three SNPs in IL6, nine in the IL-6 receptor gene (IL6R), and two in the IL-6 signal transducer gene (IL6ST).
|
30651573 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for eGFR, albuminuria, and other traditional cardiovascular risk factors, anemia (1.37, 95% CI 1.09, 1.72, <i>P</i>=0.006), insulin resistance (1.16, 95% CI 1.04, 1.28, <i>P</i>=0.006), hemoglobin A1c (1.27, 95% CI 1.14, 1.41, <i>P</i><0.001), interleukin-6 (1.15, 95% CI 1.05, 1.25, <i>P</i>=0.002), and tumor necrosis factor-α (1.10, 95% CI 1.00, 1.21, <i>P</i>=0.05) were all significantly and directly associated with incidence of heart failure.
|
28515118 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
After further adjustment for biomarkers (high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A<sub>2</sub> activity, high-sensitivity troponin I, and B-type natriuretic peptide), IL-6 remained significantly associated with the risk of major adverse cardiovascular events (adj HR Q4:Q1 1.43, 95% CI 1.09-1.88) and cardiovascular death or heart failure (adj HR 1.79, 95% CI 1.22-2.63).
|
29066436 |
2017 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both adrenergic stimulation and high levels of interleukin-6 (IL-6) indicate an unfavorable outcome in patients with myocardial infarction or heart failure.
|
31749886 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Circulating plasma concentrations of pro-inflammatory cytokines (e.g., tumor necrosis factor [TNF]-alpha and interleukin [IL]-6) are elevated in patients with heart failure and these cytokines have been shown to down-regulate CYP enzyme activity.
|
12411982 |
2002 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Higher initial levels of IL-6 in HF patients were correlated with longer distance in 6MWT one month after surgery and lower PPAR<i>γ</i> expression.
|
29093735 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, little is known regarding the association between IL-6 and clinical characteristics, outcomes and other inflammatory biomarkers in HF.
|
31087601 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, RORα protects against ANG II-mediated pathological hypertrophy and heart failure by suppressing the IL-6-STAT3 pathway and enhancing mitochondrial function.
|
30387679 |
2019 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In contrast, it has been reported that elevated serum levels of IL-6 cytokines and gp130 proteins are strong prognostic markers for morbidity and mortality in patients with heart failure or after myocardial infarction.
|
18246092 |
2008 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the CRS1 group, the mRNA expression of IL-6, IL-18 and NGAL resulted significantly higher in TECs incubated with CRS1 plasma compared with those incubated with plasma from HF and CTR (p < 0.01).
|
26228789 |
2015 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the current study, we aimed to investigate the mechanisms by which interleukin 6 induces myocardial failure in meningococcal sepsis and to identify potential novel therapeutic targets.
|
21494108 |
2011 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In women with signs and symptoms of ischemia, non-obstructive CAD and preserved EF, elevated IL-6 predicted HF hospitalization and all-cause mortality, while SAA level was only associated with all-cause mortality.
|
28542263 |
2017 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increasing evidence suggests that development of heart failure involves activation of stress-response inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-6.
|
15867183 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Maternal serum concentrations of tumor necrosis factor-α, interleukin-6, soluble Fas ligand, transforming growth factor-α, and vascular endothelial growth factor-D were significantly higher when fetuses had heart failure than when they did not (P < .05), whereas maternal serum concentrations of heparin-binding epidermal growth factor-like growth factor were significantly lower when fetuses had heart failure than when they did not (P < .05).
|
30273582 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mechanistic studies in vitro demonstrated that T lymphocyte culture supernatants stimulated by β<sub>1</sub>-AAmAb caused direct damage in the cardiomyocytes, and β<sub>1</sub>-AAmAb promoted proliferation of T lymphocytes isolated from patients with heart failure and increased IL-6 release.
|
30747396 |
2019 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, heart failure patients with high plasma Nampt levels showed suppressed cardiac TNF-α and IL-6 mRNA expression after 6 months' follow-up as well as lower B-type natriuretic peptide levels compared with heart failure patients with low Nampt plasma concentrations.
|
25498756 |
2015 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure.
|
11380590 |
2001 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that cardiac chagasic patients have an increased percentage of inflammatory monocytes and produce more IL-6, a biomarker of heart failure and left ventricular dysfunction, whereas asymptomatic chagasic individuals present a higher percentage of reparative monocytes and CCL17.
|
31379862 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results exhibited that YQFM significantly mitigated CAL-induced HF via meliorating the left ventricular contractile function and reducing the serum content of creatine kinase MB (CK-MB), aspartate aminotransferase (AST), interleukin-6 (IL-6), troponin (Tn), myosin, myoglobin (MYO) and myocilin (MYOC).
|
31505423 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Presence of metabolic syndrome (MS) and its components, presence of heart failure, severity of CAD symptoms, severe past ventricular arrhythmia (sustained ventricular tachycardia [sVT] or ventricular fibrillation [VF]), lower left ventricle ejection fraction, higher left ventricle mass index, higher end-diastolic volume and higher number of smoking pack-years were significantly associated with higher WBC, CRP and IL-6.
|
26864064 |
2016 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Proinflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor α (TNFα) have long been implicated in cardiovascular risk and considered to be a major underlying cause for heart failure (HF).
|
28763371 |
2017 |